Related Experiment Video

Updated: Apr 18, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

34.3K

Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia

Chiara Cerami1, Pasquale Anthony Della Rosa2, Giuseppe Magnani3

  • 1Università Vita-Salute San Raffaele, Milan, Italy ; Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy ; Clinical Neuroscience Department, Neurorehabilitation Unit, San Raffaele Hospital, Milan, Italy.

Neuroimage. Clinical
|January 23, 2015
PubMed

Insights

Statistical parametric mapping (SPM) analysis of [18F]FDG-PET scans accurately predicts dementia progression in mild cognitive impairment (MCI) patients. This method identifies normal metabolism or specific hypometabolic patterns, aiding early diagnosis and clinical trial selection.

Area of Science:

  • Neuroimaging
  • Neurology
  • Nuclear Medicine

Background:

  • Mild cognitive impairment (MCI) is clinically heterogeneous, complicating early diagnosis of underlying Alzheimer's Disease (AD) pathology.
  • Fluorodeoxyglucose Positron Emission Tomography ([18F]FDG-PET) is a key imaging biomarker for AD in MCI.
  • Predicting dementia subtype progression in MCI remains a challenge.

Purpose of the Study:

  • To evaluate the predictive value of single-subject voxel-based [18F]FDG-PET maps using Statistical Parametric Mapping (SPM) for dementia progression in MCI.
  • To differentiate between normal metabolism, AD, frontotemporal lobar degeneration (FTLD), and dementia with Lewy bodies (DLB) patterns in MCI.
  • To assess the utility of SPM [18F]FDG-PET analysis for early dementia diagnosis and clinical trial subject selection.

Main Methods:

  • Retrospective analysis of [18F]FDG-PET scans from 45 MCI subjects compared to a normal reference dataset.
  • Voxel-based analysis using SPM to generate single-subject metabolic maps.
  • Clinical follow-up (mean 28.5 months) to determine progression to AD or non-AD dementias.
  • Cerebrospinal fluid (CSF) Aβ42 and Tau levels available for 34 subjects.

Main Results:

  • 14 MCI cases showed normal metabolism and did not progress to dementia.
  • 15 cases exhibited temporo-parietal hypometabolism suggestive of prodromal AD, with 11 progressing to AD.
  • 10 cases showed hypometabolism indicative of FTLD (7) or DLB (2), and all progressed to respective diagnoses.
  • 7 cases had stable temporo-medial hypometabolism without typical AD patterns, remaining stable.

Conclusions:

  • Objective voxel-based [18F]FDG-PET analysis via SPM demonstrates high prognostic value in MCI.
  • This method effectively identifies normal brain metabolism and specific hypometabolic patterns associated with different dementia pathologies.
  • SPM [18F]FDG-PET analysis shows promise for early dementia diagnosis and optimizing MCI patient selection for clinical trials.
Keywords:
Alzheimer's diseaseDementia diagnosisMild Cognitive ImpairmentPET imaging[18F]FDG

More Related Videos

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

16.5K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.6K

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
1
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
2
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
734
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
1